Long ‐term effects of crizotinib in ALK‐positive tumors (excluding NSCLC): A phase 1b open‐label study

This article is protected by copyright. All rights reserved.

Source: American Journal of Hematology - January 20, 2018 Category: Hematology Authors: Carlo Gambacorti ‐Passerini, Sergey Orlov, Li Zhang, Fadi Braiteh, Huiqiang Huang, Taito Esaki, Keizo Horibe, Jin‐Seok Ahn, Joseph T. Beck, William Jeffrey Edenfield, Yuankai Shi, Matthew Taylor, Kenji Tamura, Brian A. Van Tine, Shang‐Ju Wu, Jolanda Tags: Research Article Source Type: research